Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib

Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib

US Patent 11497756 · Granted Nov 15, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Inhibitors of LRRK2 kinase2025
Antimitotic amides for the treatment of cancer and proliferative disorders2025
Alvocidib prodrugs having increased bioavailability2025
Alvocidib prodrugs having increased bioavailability2025
CDK9 inhibitors2025
Inhibitors of NEK7 kinase2024
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer2024
Inhibitors of LRRK2 kinase2024
Treatment of acute myeloid leukemia (AML) with venetoclax failure2023
ALK-5 inhibitors and uses thereof2023
ALK-5 inhibitors and uses thereof2023
Compositions comprising PKM2 modulators and methods of treatment using the same2023